All News

FDA approves a new combination therapy for BRCA2-mutated metastatic prostate cancer, showing significant efficacy in clinical trials.

Exploratory findings from the MONALEESA-3 trial presented at SABCS 2025 show ribociclib plus fulvestrant significantly enhances survival in ILC.

Discover how antibody drug conjugates (ADCs) are transforming treatment for HER2-positive breast cancer with brain metastases at SABCS 2025.

SABCS showcases emerging trends in breast cancer treatment, emphasizing pharmacists' vital role in medication management and patient care strategies.

Kelly Gable, professor and director of well-being and resilience at Southern Illinois University Edwardsville School of Pharmacy, discusses her own cancer journey and how pharmacists need to be more involved and proactive in patients' mental health.

Explore innovative biomarkers to enhance immunotherapy for early-stage TNBC, aiming to improve patient outcomes and treatment precision.

Effective Nutrition Strategies for Diabetes Management Focus on Personalized Dietary Approaches to Enhance Glycemic Control and Overall Health

After 2 initial doses, inebilizumab is administered with only 2 doses a year.

As the new chair of the Advisory Committee on Immunization Practices (ACIP) signals interest in revisiting childhood and adolescent vaccine schedules, immunologist Morgan McSweeney, PhD, stresses that any changes must be anchored in decades of rigorous safety and efficacy data.

New research reveals that low cholesterol levels may indicate increased severity in Crohn's disease, offering a potential new biomarker for monitoring inflammation.

Aflibercept biosimilar QL1207 shows comparable efficacy to the reference drug in treating diabetic macular edema, offering a potentially affordable treatment option for those facing adherence and accessibility issues.

Experts explore the evolving role of HER2- and TROP2-targeted therapies in breast cancer treatment at SABCS 2025, highlighting ADC advancements.

Explore the pleiotropic effects of GLP-1 agents in oncology care, highlighting their benefits and considerations for pharmacists and clinicians.

FDA approves gepotidacin as a new oral treatment for uncomplicated gonorrhea, expanding options against resistant sexually transmitted infections.

Explore the HER2CLIMB-05 study's findings on tucatinib's impact on breast cancer progression-free survival, enhancing treatment options for pharmacists.

Policy Needs to Catch Up to the People Behind the Counter

Latest findings presented at SABCS 2025 support trastuzumab deruxtecan's effectiveness and safety in treating HER2-positive breast cancer.

The FDA approves Flow's at-home depression treatment headset, offering a new approach to managing mental health with transcranial stimulation technology.

New research highlights the benefits of adding isatuximab to standard therapy for newly diagnosed multiple myeloma (NDMM), improving patient outcomes and quality of life.

Diana Isaacs, PharmD, highlights evolving criteria for insulin pump therapy in type 2 diabetes.

Ginger Thorpe discusses how in-house specialty pharmacy models enhance patient care, streamline communication, and boost health system revenue amid rising demand.

Tucatinib enhances first-line maintenance therapy for HER2-positive metastatic breast cancer, improving progression-free survival and safety outcomes, as shown in the HER2CLIMB-05 trial.

Cell-cycle–focused CDK inhibitors offer new options for HR+/HER2– metastatic breast cancer after CDK4/6 resistance.

Pharmacists play a vital role in precision oncology, enhancing treatment decisions for metastatic breast cancer through genetic testing and targeted therapies.

Pharmacists play a crucial role in improving BRCA testing rates for metastatic breast cancer, enhancing patient access to targeted therapies.

New findings highlight the need for pneumococcal booster vaccinations in children with sickle cell disease to maintain immunity and prevent serious complications.

Allegheny General Hospital enhances pharmacy operations through centralized, robotics-enabled IV compounding, boosting efficiency and patient care.